Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and ...

Please provide your email address to receive an email when new articles are posted on . There are limited numbers of FDA-approved medications to treat alcohol and substance use disorders. Preclinical ...

Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

In 524,817 adults with T2D, GLP-1 RA use was associated with lower incident alcohol, cocaine, cannabis, opioid, and nicotine ...

The COVID-19 pandemic has created both short-term and long-term negative consequences for behavioral health outcomes. The National Academies of Sciences, Engineering, and Medicine's Forum on Mental ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be ...

Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

Polysubstance use disorder is a mental health condition in which someone uses more than one substance at the same time or within a short period of time, despite a pattern of negative effects.

SANTA ANA, CA - March 16, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource detailing ...